The role of inflammatory cytokines in diabetes and its complications

Journal of Periodontology

Volumn 79, Issue 8 SUPPL., 2008, Pages 1527-1534

  King, George L ^a,b,c  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Joslin Clinic   (United States)

Author keywords

Complications; Diabetes; Hyperglycemia; Inflammation; Insulin resistance; Periodontal disease

Indexed keywords

AUTACOID; CYTOKINE;

CONFERENCE PAPER; DIABETES MELLITUS; HUMAN; IMMUNOLOGY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIODONTAL DISEASE;

CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; OBESITY; PERIODONTAL DISEASES;

EID: 49449117005     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.080246     Document Type: Conference Paper

References (39)

1. (CDC) Center for Disease Control and Prevention. Diabetes data & trends. Number (in millions) of persons with diagnosed diabetes, United States, 1980-2005. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/ figpersons.htm. Accessed February 9, 2008.
2. (CDC) Center for Disease Control and Prevention. Diabetes data & trends. Overweight and obesity. U.S. Obesity Trends 1985-2006. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/. Accessed February 9, 2008.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
4. Soskolne WA, Klinger A. The relationship between periodontal diseases and diabetes: An overview. Ann Periodontol 2001;6:91-98.
5. (CDC) Center for Disease Control and Prevention. National diabetes fact sheet. United States, 2005 General information. Available at: http://apps.nccd.cdc.gov/DDTSTRS/template/ndfs_2005.pdf. Accessed February 9, 2008.
6. Singh R, Shaw J, Zimmet P. Epidemiology of childhood type 2 diabetes in the developing world. Pediatr Diabetes 2004;5:154-168.
7. Treszl A, Szereday L, Doria A, King GL, Orban T. Elevated C-reactive protein levels do not correspond to autoimmunity in type 1 diabetes. Diabetes Care 2004;27:2769-2770.
8. Devaraj S, Cheung AT, Jialal I, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007;56:2790-2796.
9. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455-461.
10. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
11. Thorand B, Löwel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: Results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-99.
12. Mooradian AD. Obesity: A rational target for managing diabetes mellitus. Growth Horm IGF Res 2001;11(Suppl. A):S79-S83.
13. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801.
14. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867.
15. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664-671.
16. Albert MA, Ridker PM. C-reactive protein as a risk predictor: Do race/ethnicity and gender make a difference? Circulation 2006;114:e67-e74.
17. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
18. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-885.
19. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-1677.
20. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-294.
21. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002;30:182-192.
22. Scott JA, King GL. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci 2004;1031:204-213.
23. He Z, King GL. Protein kinase C beta isoform inhibitors: A new treatment for diabetic cardiovascular diseases. Circulation 2004;110:7-9.
24. Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005;16(Suppl. 1):S78-S82.
25. Izuora KE, Chase HP, Jackson WE, et al. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care 2005;28:714-715.
26. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:4295-4301.
27. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007;55:498-510.
28. He Z, King GL. Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients? Diabetes Care 2005;28:2803-2805.
29. Ohshiro Y, Ma RC, Yasuda Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice. Diabetes 2006;55:3112-3120.
30. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
31. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(dimethylamino) methyl]-10,11,14,15-tetrahydro-4, 9:16, 21-dimetheno-1H, 13H-dibenzo[e,k] pyrrolo[3, 4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39:2664-2671.
32. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-2026.
33. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439-447.
34. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686-2690.
35. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-2230.
36. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318-324.
37. Al-Zahrani MS, Bissada NF, Borawski EA. Obesity and periodontal disease in young, middle-aged, and older adults. Journal of Periodontology 2003;74:610-615.
38. Genco R, Grossi S, Ho A, Nishimura F, Murayama Y. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. Journal of Periodontology 2005;76:2075-2084.
39. Ritchie C. Obesity and periodontal disease. Periodontology 2000 2007;44:154-163.